“JB Pharma delivered a good quarter driven by focused execution.
Our domestic business continued its growth trajectory through strong momentum in
our chronic portfolio and acquired assets. Our big brands, especially in chronic segment,
continue to outpace the market and have reached new milestones. CDMO business
scaled further during the quarter and the healthy momentum continues for this
segment too.
EBITDA margins improved during the quarter on account of better business mix,
increased efficiencies in sourcing, and higher volumes. The first quarter has been a
robust performance both in terms of topline and operating profit, and we remain
positive about delivering on our business objectives. We will maintain our distinctive
focus on India and the CDMO business, while maintaining our efforts to control costs &
increase efficiencies across the organisation.”
| Subscribe To Our Free Newsletter |
